http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018056865-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9dabf5c4d8118c4b696e19078b3a745
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
filingDate 2017-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60f1639afc5623f791cbf4c13a3d5f47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f6ea019338fb9462da14ab8fd26b1f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7ae16caa454eb79e33c974be474d386
publicationDate 2018-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2018056865-A1
titleOfInvention Pharmaceutical composition for treating hiv infection
abstract The invention relates to the field of the pharmaceutical chemical industry. The present pharmaceutical composition for treating HIV infection comprises lopinavir and ritonavir in an effective amount, and a polymer. The pharmaceutical composition is produced by extrusion. The composition comprises, as the polymer, a matrix polymer consisting of PEG 6000 / vinylcaprolactam / vinyl acetate, at 5 to 25 % of the mass of the pharmaceutical composition, in combination with copovidone, at 45 to 65 % of the mass of the pharmaceutical composition. This invention makes it possible to broaden the range of available drugs with improved pharmacokinetic properties.
priorityDate 2016-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013190337-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-011924-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016193151-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID92727
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID392622
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226410983
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226420543
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID17881685
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398153

Total number of triples: 37.